PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that it received approval from its European Notified Body to expand the CE Mark indications of the Self-Apposing stent. Patients suffering from chronic chest pain due to narrowed coronary arteries are often treated with a stent. Coronary arteries generally have cy
Reported by Business Wire 4 days ago.
↧
